Trelegy Recovers, but HIV Timing and the 2027 Interest Bill Limit the Re-rating
Key Takeaways
- The operating recovery passed its most immediate test. General Medicines recovered from a 9% CER decline to flat, while Specialty grew 15%. Core EPS of 54.6p beat 50.4p consensus, although inventory, spending phasing and royalties make the surprise less durable than the headline suggests.
- The HIV succession case has become less certain again. Analysis of four-monthly prevention data is ongoing ahead of regulatory discussions. Management sees no read-through to treatment, but has not supplied the evidence needed to dismiss that risk.
- Hibsago clears the prior label test; financing gets harder. The US approval extends to eligible patients with surface antigen levels up to 3,000 IU/ml, while management indicated 2027 net finance costs of £900m–£1bn. The pipeline is advancing faster than near-term earnings.
- Rating: Maintaining Outperform, with lower conviction. Our 12-month target falls from $62 to $57 per ADS. Expected price upside of 16.9% plus approximately 3.8% in dividends still offers an attractive return, but less certainty around the HIV bridge warrants a lower multiple.
Results vs. Consensus
All financial amounts are sterling unless labelled otherwise. Core figures exclude adjusting items and are non-IFRS; Total figures are IFRS. Growth in operating commentary is at constant exchange rates (CER), while table comparisons of sterling amounts use actual exchange rates (AER). One US ADS represents two ordinary shares.
| Q3 2026 metric | Actual | Consensus | Beat / miss |
|---|---|---|---|
| Turnover | £8,887m | £8,840m | Beat: 0.5% |
| Core EPS | 54.6p | 50.4p | Beat: 8.3% |
| Core operating profit | £3,076m | n/a | n/a |
| Total EPS | 38.5p | n/a | n/a |
| Free cash flow | £2,078m | n/a | n/a |
Year-over-year comparison
| £m except EPS and margins | Q3 2026 | Q3 2025 | Change, AER |
|---|---|---|---|
| Turnover | 8,887 | 8,547 | 4.0% |
| Core gross profit | 6,847 | 6,488 | 5.5% |
| Core gross margin | 77.0% | 75.9% | +110bps |
| Core SG&A | 2,155 | 2,159 | -0.2% |
| Core R&D | 1,874 | 1,552 | 20.7% |
| Royalty income | 258 | 208 | 24.0% |
| Core operating profit | 3,076 | 2,985 | 3.0% |
| Core operating margin | 34.6% | 34.9% | -30bps |
| Core net finance expense | 197 | 132 | 49.2% |
| Core EPS | 54.6p | 55.0p | -0.7% |
| Total operating profit | 2,127 | 2,593 | -18.0% |
| Total EPS | 38.5p | 49.9p | -22.8% |
| Free cash flow | 2,078 | 1,246 | 66.8% |
Quarter-over-quarter comparison
| Metric | Q3 2026 | Q2 2026 | Sequential change |
|---|---|---|---|
| Turnover (£m) | 8,887 | 8,409 | 5.7% |
| Core operating profit (£m) | 3,076 | 2,800 | 9.9% |
| Core operating margin | 34.6% | 33.3% | +130bps |
| Core R&D (£m) | 1,874 | 1,721 | 8.9% |
| Core EPS | 54.6p | 50.5p | 8.1% |
| Total EPS | 38.5p | 10.8p | 256.5% |
| Free cash flow (£m) | 2,078 | 1,994 | 4.2% |
Quality of the beat
Revenue: Specialty remains the demand engine, but the quarter also borrowed from later periods. Management identified US Shingrix inventory, meningitis ordering and Ventolin phasing. General Medicines stabilisation is a meaningful improvement over July’s concern, although positive pricing adjustments helped Trelegy and other respiratory brands. The small group sales beat does not justify extrapolating every product’s Q3 growth.
Margins: Gross profit rose £359m and SG&A was nearly flat, but R&D absorbed £322m of the improvement. Higher royalties added £50m, more than half the £91m increase in reported Core operating profit. The mix shift is funding drug development rather than producing immediate operating-margin expansion. That is consistent with the strategy; it also leaves the earnings-quality risk active.
EPS: The 8.3% beat against sterling consensus coexists with a small reported year-on-year decline. Net finance costs rose £65m and the Core tax rate increased to 17.0% from 16.0%. Total EPS is substantially below Core EPS, including £328m of Accelerate Growth restructuring charges. Conversely, the sequential rebound in Total EPS largely reflects the absence of Q2’s camlipixant impairment, not a comparable jump in recurring profitability.
Segment Performance
| Product group / franchise | Q3 turnover, £m | Growth, CER | Q2 turnover, £m |
|---|---|---|---|
| Specialty Medicines | 3,877 | 15% | 3,782 |
| HIV (within Specialty) | 2,116 | 10% | 2,078 |
| Respiratory, Immunology & Inflammation | 1,139 | 21% | 1,135 |
| Oncology | 622 | 23% | 569 |
| Vaccines | 2,583 | -2% | 2,284 |
| General Medicines | 2,427 | Flat | 2,343 |
| Group total | 8,887 | 5% | 8,409 |
Specialty: demand is working, while the launch base remains small
Cabenuva grew 35% to £478m and Apretude 21% to £143m. Long-acting injectables supplied 80% of HIV growth and remained 35% of US HIV turnover. Respiratory growth included Nucala at £582m and Exdensur at £27m; Oncology reached £622m, with Blenrep at £50m and Ojjaara at £195m. These are several distinct growth contributors rather than dependence on a single launch.
More than 75% of switches continue to come from competitors in the U.S., and Cabenuva remains the only long-acting injectable regimen for HIV treatment, establishing a strong foundation with patients who prefer to take medicines less frequently.
— Nina Mojas, Chief Commercial Officer
Assessment: The standing Specialty pillar remains on track. Its share of turnover is 43.6%, below Q2’s 45.0% because the quarterly sales mix is seasonal; the year-on-year growth rate, not an uninterrupted sequential share gain, is the useful test. Current injectable demand supports earnings even as uncertainty rises around the next formulation. We retain double-digit Specialty growth in our 2027 operating assumptions.
Vaccines: channel support masks a weaker consumer backdrop
Shingrix fell 5% to £780m and Arexvy fell 24% to £195m. Meningitis grew 12% to £599m, helped by Penmenvy uptake and stockpile ordering. The US Shingrix channel build added two percentage points to global Shingrix growth, while China continued to work through inventory. US pharmacy inventory was 2.3m doses against 1.7m a year earlier; this raises the risk that shipments run ahead of vaccinations.
But we do need to balance that with the fact that the adult market overall, adult vaccines market overall is still challenging.
— Luke Miels, Chief Executive Officer
Assessment: The comp wall is no longer merely a contained timing issue. Shingrix declines despite inventory support, and management expects another difficult China comparator in Q4. We move the vaccine risk to EMERGING. Meningitis offsets part of the weakness, but its ordering contribution cannot establish a durable adult-vaccine recovery.
General Medicines: the promised recovery arrives
General Medicines was flat at CER after declining 9% in Q2. Trelegy grew 8% to £787m, with the US returning to growth as Medicare patients progressed through deductibles and adjusted to co-insurance. The remainder of the portfolio still faces generic erosion; Other General Medicines declined 3%.
In the U.S., Trelegy returned to growth, up 8% as patients reached their Medicare deductibles and adjusted to co-insurance.
— Nina Mojas, Chief Commercial Officer
Assessment: July’s explicit downside trigger, another 9% segment decline without Trelegy stabilisation, did not occur. That materially strengthens the FY2026 operating case. It does not settle 2027: negotiated US prices for Trelegy and Breo create a new reset, and the discount to list price is not the same as the reduction in GSK’s realised net revenue.
Key KPIs
| Indicator | Q3 2026 | Q2 2026 | Investment implication |
|---|---|---|---|
| Specialty share of turnover | 43.6% | 45.0% | Sequential seasonality; structural growth remains strong |
| Long-acting share of total HIV sales | 29.3% | 28.5% | Growing recurring franchise |
| Exdensur sales | £27m | £18m | Launch expands from a small base |
| Blenrep sales | £50m | £36m | Adoption improving |
| Core R&D / sales | 21.1% | 20.5% | Higher reinvestment |
| Net debt / Core EBITDA | 1.8x | 1.4x pre-Nuvalent (prior report) | Capacity reduced by acquisition |
Key Topics & Management Commentary
Overall Management Tone: Management was confident about operating delivery but more guarded on the HIV data than at July’s strategy event. The willingness to acknowledge ongoing analysis is useful; repeated assurances about treatment cannot substitute for the missing technical explanation.
1. HIV prevention uncertainty reverses part of July’s confidence gain
July’s upgrade to the HIV pillar relied on a three-times-yearly prevention launch in 2027 and a treatment successor inside the dolutegravir loss-of-exclusivity window. EXTEND 4M data are now in-house, but analysis is continuing and management has not reaffirmed the earlier prevention launch timetable. The issue matters commercially because competitors are already offering longer dosing intervals.
We have the data in-house. The analysis is ongoing. We look forward to sharing with the regulators. Obviously, we will update the market once that analysis is complete.
— David Redfern, Chair, ViiV Healthcare
Assessment: This is uncertainty about timing and characterisation, not a disclosed trial failure. We move Bull 2 back to AT RISK. The prevention and treatment trials ask different questions, but use the same formulation; until the underlying explanation is available, a modest valuation discount is warranted even though current HIV sales are healthy.
2. Treatment retains its own evidence path
CUATRO is fully recruited with a 2027 readout expected, and compares four-monthly treatment with two-monthly Cabenuva on efficacy. CROWN’s positive headline in unsuppressed patients offers another route to expand the existing treatment franchise. Six-monthly agents remain in phase II, with a pivotal study intended for 2028.
Just to remind you, it is an efficacy study comparing four months with two-monthly Cabenuva, but that's obviously now very much on track to read out next year.
— David Redfern, Chair, ViiV Healthcare
Assessment: We retain the treatment opportunity rather than writing off all long-acting HIV because prevention is unresolved. However, the earlier CONTAINED tag on dolutegravir risk was supported partly by confidence in the entire succession programme. We return that risk to EMERGING until the formulation question is addressed or treatment data provide independent reassurance.
3. Hibsago approval passes the label test, but launch execution replaces regulatory risk
US approval on 20 October covers eligible adults without cirrhosis on nucleos(t)ide therapy for at least six months, with suppressed HBV DNA and HBsAg levels no higher than 3,000 IU/ml. That is broader than the sub-1,000 restriction identified as a downside trigger in July. Management nevertheless intends to concentrate initial uptake in lower-antigen patients, where response is more favourable. Monitoring for liver enzyme elevations and platelet reductions adds work for physicians and patients.
We have launched with a focus on patients with surface antigen level lower than 1,000, where the opportunity to have a positive experience leading to functional cure is the highest.
— Nina Mojas, Chief Commercial Officer
Assessment: A commercial focus on the best responders is distinct from a restrictive approval. The prior label trigger was avoided, supporting the pipeline pillar. We introduce a modest £150m 2027 sales assumption across markets rather than a rapid prevalent-patient surge; uptake, reimbursement and monitoring will determine whether this becomes a material earnings contributor.
July’s oncology commitments also advanced. Jemperli received accelerated US approval for locally advanced dMMR/MSI-H rectal cancer, resolving the earlier submission-and-decision watch item. Jideytro launched in previously treated ROS1-positive lung cancer and contributed £3m, while encouraging first-line data expand its potential; neladalkib’s November decision remains ahead. These developments support the rationale for Nuvalent and the broader pipeline, but £3m of initial sales is far from offsetting the acquisition’s financing bill. We retain staged launch contributions rather than treating approvals as immediate earnings accretion. Exdensur’s OCEAN readout remains an H2 2026 milestone; the Arexvy immunocompromised label update was approved in July.
4. Exdensur’s access milestone comes in two stages
The July J-code arrived as promised, but the reimbursement pricing document followed on 1 October. Prescriber growth and patient starts improved during Q3, with starts including free first doses. Paid sales of £27m therefore remain the more useful financial checkpoint than the patient-start growth rate alone.
As a result, new prescribers in the U.S. were up 68% in Q3, and new patient starts were up 74% when we include those who received the free first dose through our Fast Start program.
— Nina Mojas, Chief Commercial Officer
Assessment: The access explanation is credible and more specific than a general promise of a better launch. Our base case allows acceleration after October, but does not convert every new start into revenue immediately. Blenrep’s £50m sales and increasing repeat prescribing similarly support growth without yet proving a mature launch trajectory.
5. Accelerate Growth is happening faster, including the cost
Eighteen of the planned 22 phase III starts are underway. R&D rose 22% at CER, while SG&A rose only 1%; the resource shift promised in July is visible in the accounts. Expected 2026 restructuring charges increased from £0.7bn to as much as £1bn, although the programme’s £1.9bn annual savings ambition remains unchanged.
The Accelerate Growth program is all about removing cost from what you may call support services and some of the manufacturing network, and it is moving it towards the front line of R&D.
— Julie Brown, Chief Financial Officer
Assessment: The programme supports pipeline capacity, but a faster charge is not itself a higher savings target. We continue to assume much of the productivity benefit is reinvested. The stable-to-improving 2028–2030 margin outlook remains valuable, while the precise 2027 margin is still an open question.
6. The acquisition’s financing cost extends into 2027
Management lowered 2026 expected net finance costs to £700m–£750m, yet indicated roughly £900m–£1bn for 2027, including more than £300m of Nuvalent-related interest. Better current cash generation does not remove the full-year financing burden or restructuring cash demands.
In terms of the overall interest charge, we will guide this at the end of the year, but it is going to be in the order of GBP 900 million to maybe GBP 1 billion.
— Julie Brown, Chief Financial Officer
Assessment: We use £950m in 2027 against £725m in 2026. At a 17.5% tax rate and roughly 4bn shares, that £225m increase costs approximately 4.6p of EPS. This makes sustained operating growth essential merely to produce modest bottom-line progress. The valuation-and-capital-return pillar remains AT RISK despite leverage improving from the post-deal level.
Guidance & Outlook
| FY2026 metric | July position | October position | Change |
|---|---|---|---|
| Turnover growth, CER | 3–5%, upper half | 3–5%, upper half | Maintained |
| Core OP growth, CER | 7–9%, upper half | 7–9%, upper half | Maintained |
| Core EPS growth, CER | 7–9%, lower half | 7–9%, lower half | Maintained |
| Core operating margin, CER | More than 31% | More than 31% | Maintained |
| Royalty income | £850m–£900m | Around £900m | Raised |
| Net finance costs | Around £800m | £700m–£750m | Lower |
| Core tax rate | Around 17.5% | Around 17.5% | Maintained |
| Dividend per ordinary share | 70p | 70p | Maintained |
Nine-month turnover is £24,925m, Core operating profit £8,526m and Core EPS 151.6p. Our reported-sterling FY2026 estimates of £33.8bn sales, £10.35bn Core operating profit and 182p Core EPS imply Q4 of £8.875bn, £1.824bn and 30.4p respectively. Against Q4 2025’s £8.618bn, £1.634bn and 25.5p, those assumptions require approximately 3.0% sales growth, 11.6% operating-profit growth and 19.2% EPS growth at actual exchange rates. The EPS comparison benefits from last year’s weak fourth quarter; it is not an acceleration to a new annual growth rate.
This forecast sits alongside, rather than mechanically reproducing, the CER guide. Company currency sensitivities improved to a one-point drag on annual sales growth and a three-point drag on Core operating-profit growth, versus two and four points in July. At the same time, management expects Q4 sales growth to moderate on HIV pricing and Shingrix comparators. Better royalties and interest therefore help absorb weaker phasing rather than supporting an automatic guide increase.
On an approximate constant-currency basis, the upper-half annual sales guide implies roughly 1–5% Q4 growth, the upper-half operating-profit guide roughly 13–19%, and the lower-half EPS guide roughly 13–20%. These ranges use rounded nine-month CER growth of 5%, 7% and 6%, respectively, against the prior-year weights. They reinforce July’s warning that profit growth is fourth-quarter weighted; they are sensitivities, not precise quarterly company guidance.
Assessment: The unchanged ranges are credible but still require a stronger fourth-quarter profit comparison. Our FY2026 EPS rises from July’s approximate 180p reported-sterling equivalent to 182p, reflecting the beat, lower finance expense and better currency, with a substantial part of the Q3 upside treated as timing. We do not carry the full consensus surprise into next year.
Analyst Q&A Highlights
Why treatment can differ from prevention
Q: I understand there's limited amount you can say about Q4 treatment, as in CAB treatment, and the read across from the PrEP dose, but it's the same tech, it's the same product. You clearly had an outcome with the PrEP data, the PK/PD study, that didn't exactly tell you what you were hoping for. You're saying there is no read across into treatment. How can you make that statement? How can you give us confidence that there isn't any read across?
— Michael Leuchten, Jefferies
A: EXTEND, which is the PrEP study, and CUATRO, which is the treatment study, are very different studies. So EXTEND is a PK bridging study where we are looking at drug substance levels at steady state, no earlier than month 13, as well as safety and tolerability. The CUATRO study is an efficacy study comparing the four-monthly formulation of cabotegravir and rilpivirine with two-monthly Cabenuva.
— David Redfern, Chair, ViiV Healthcare
Assessment: The question concerned potential read-through from the prevention study to treatment using the same formulation. The answer explains the different endpoints but supplies no pharmacokinetic result that resolves the concern. That supports retaining the treatment opportunity with lower confidence, not declaring it impaired or fully insulated.
When the prevention data might become clearer
Q: I am sorry, just a very quick follow-up on APRETUDE Q4M. Just interested to know whether you do have a date scheduled to review that data with the FDA, whether you can share that with us. Ultimately, when can we expect more clarity on the issues here in the next steps?
— Kerry Holford, Berenberg
A: I think what I can tell you, Kerry, is we have reached steady state for the last patient only a few weeks ago, not very long ago. So the analysis, as we have said, is ongoing. I think we are confident we will be sharing the data with the regulator before the end of the year, and obviously, post-regulatory discussions, we will update appropriately. So that sort of timing, but I cannot be more specific than that.
— David Redfern, Chair, ViiV Healthcare
Assessment: The question followed a request for the timing of FDA discussions on four-monthly Apretude. The commitment is to share data by year-end, not to obtain agreement or launch on a specified date. That becomes the next observable milestone for the HIV pillar.
Why a beat did not raise the guide
Q: Then as we think about the guidance for the full year, you beat very nicely on SG&A, in particular in the third quarter, but the guidance doesn't go up. So just the pushes and pulls on why not, given you do have some slight help from the royalty income and also lower net financials into the end of the year.
— Michael Leuchten, Jefferies
A: Sales were higher than our original expectations, and this included some phasing between Q3 and Q4. As we mentioned, we had the U.S. Shingrix inventory build, meningitis ordering patterns, and we also had Ventolin impacting the quarter.
— Julie Brown, Chief Financial Officer
Assessment: The question challenged unchanged guidance despite the Q3 beat and favourable royalty and financing assumptions. The response identifies specific timing benefits. Our forecast retains part of the upside but does not annualise a quarter helped by inventory and orders.
Whether higher R&D can coexist with 2027 margin improvement
Q: Then if we think into next year, and I appreciate you won't be wanting to give guidance at this point, but just given the commentary you made, Julie, on the OpEx in Q4, in the context of those phase three starts this year, and at least I think you highlighted six additional phase III starting next year, how confident are you that the necessary incremental R&D spend moving into next year can be offset by SG&A savings and COG savings in 2027?
— Kerry Holford, Berenberg
A: So we do expect R&D to continue to grow ahead of sales. You will be pleased to know not to the extent of Q3, which was obviously very high. But as demonstrated, we can deliver profitable growth through the efficiency in both the cost of goods, and we have talked about the specialty pivot together with the SG&A.
— Julie Brown, Chief Financial Officer
Assessment: The mechanisms are plausible and Q3 shows gross-margin and SG&A efficiency, but this still is not a quantified 2027 margin commitment. We assume modest profit growth after reinvestment, with no automatic margin windfall from the savings programme.
Whether the debt bill is fully reflected in expectations
Q: On 2027 net financial charge, you've highlighted the strong cash flow, but obviously the cash out for Nuvalent and for the restructuring program. Do you think that consensus has next year's net financial charge modeled correctly or we need to sharpen our pencils?
— Matthew Weston, UBS
A: So in terms of the financial charge, we have guided for the second half of this year that Nuvalent will be GBP 160 million, so it gives you an idea about how much it will cost us next year in terms of interest. It is going to be over GBP 300 million.
— Julie Brown, Chief Financial Officer
Assessment: The question explicitly concerned 2027 financing after acquisition and restructuring outflows. The answer confirms the full-year acquisition burden; the separate indication of £900m–£1bn total finance expense provides the more useful modelling range. The lower 2026 bill should not be extrapolated.
What They’re NOT Saying
- The numerical EXTEND result and revised launch date. The formulation analysis and regulatory path are unresolved. Assurance about CUATRO is not disclosure of the prevention data.
- A quantified 2027 margin bridge. The direction of reinvestment is clear, but the split of savings between R&D and earnings remains undisclosed.
- Hibsago’s early paid-patient conversion. Approval and initial physician interest do not reveal how monitoring and reimbursement will affect uptake.
- A successor buyback. The completed £2bn programme has no announced replacement; our estimates assume no material new share-count reduction.
Market Reaction
The ADS closed at $50.94 before the print, up 3.9% year to date against 12.8% for the S&P 500. It was up 16.6% over twelve months and 2.5% over thirty days. On 28 October it opened at $47.65, traded between $47.36 and $49.32, and closed at $48.74, down 4.3%. Volume of 8.1m was 1.6 times its thirty-day average; the S&P 500 rose 0.3%.
The decline despite an earnings beat is consistent with investors assigning more weight to future growth and vaccine weakness than to a quarter helped by phasing. The partial recovery from the opening gap suggests the initial reaction was harsher than the closing judgment. These daily prices cannot isolate how much of the fall came from the HIV disclosure, launch performance or financing outlook. Our own conclusion is that the changed confidence in the succession programme matters more to valuation than the near-term EPS beat.
Street Perspective
Does pipeline breadth compensate for uncertainty in HIV?
Bull view: Approvals and 22 planned phase III starts diversify GSK beyond its older HIV franchise. Current Cabenuva growth and treatment development remain intact.
Bear view: More studies also mean more spending, while the four-monthly prevention question affects one of the most important franchise transitions.
Our take: Breadth supports the long-run opportunity but cannot eliminate formulation-specific risk. We retain the Specialty and pipeline pillars while reducing the multiple to recognise less certainty around HIV.
Is the vaccine shortfall temporary?
Bull view: China destocking and seasonal ordering distort shipments; broader international access and meningitis growth offer offsets.
Bear view: Weak adult vaccination demand persists and US Shingrix growth has inventory support. A return to shipments need not mean a durable increase in vaccinations.
Our take: The bears have the stronger near-term case. We assume roughly stable 2027 vaccine sales rather than a rebound that finances the R&D programme.
Can cost savings protect earnings after the acquisition?
Bull view: Specialty mix and productivity are already funding substantially higher R&D without a large operating-margin decline.
Bear view: Financing, US pricing and lost royalties arrive before many pipeline revenues. Restructuring cash costs also constrain capital returns.
Our take: Operating resilience is credible, but earnings growth will be slower than the headline Specialty rate. Our 2027 EPS estimate increases only modestly from 2026, and the rating depends on the price paid for that trajectory.
Our Estimates & Valuation
| Analyst estimate | July view | Updated view | Reason |
|---|---|---|---|
| FY2026 Core EPS | 185p CER; approximately 180p reported | 182p reported sterling | Beat, lower interest and less FX drag; offset by phasing |
| FY2027 Core EPS | 195p CER | 187p reported sterling | Explicit currency rebasing and lower net earnings growth |
| FY2026 turnover | 4.5% CER growth | £33.8bn reported | About 3.5% AER growth |
| FY2026 Core operating profit | n/a | £10.35bn reported | Q4 £1.824bn implied |
| FY2027 net finance expense | Full-year Nuvalent drag anticipated | £950m | Midpoint of indicated range |
| FY2027 Hibsago turnover | Nil | £150m | Measured launch after approval |
| Valuation multiple | 12.0x FY2027 Core EPS | 11.5x FY2027 Core EPS | Less confidence in HIV succession |
| 12-month ADS target | $62 | $57 | Lower EPS base and multiple |
The prior 195p FY2027 estimate was expressed at constant currency. We first rebase it to approximately 190p reported sterling, using a 5p translation allowance consistent with the prior report’s distinction between constant-currency and reported earnings. The further 3p net cut reflects financing and pricing risks after allowing for modest new-launch contribution. This is a change in presentation basis as well as a reduction in the operating investment case; the entire 8p difference is not an earnings downgrade.
Our independent year-on-year bridge starts at 182p FY2026 Core EPS. We assume 14p of operating contribution from Specialty growth, new launches and productivity net of higher R&D, then subtract 4.6p for higher net finance expense, 3p for US pricing and established-product erosion, and 1.4p for the fourth-quarter loss of the Biktarvy royalty. That produces approximately 187p in FY2027. The 14p contribution implies roughly £680m of pre-tax improvement at a 17.5% tax rate and 4bn shares. It assumes low-double-digit Specialty growth, broadly stable Vaccines and no successor buyback. These are analyst assumptions, not company guidance.
The royalty sensitivity reflects management’s £70m quarterly headwind beginning in October 2027, not a full £280m loss in that year. Similarly, the financing bridge measures the increase from our £725m 2026 estimate to £950m in 2027, rather than charging the acquisition’s entire annual interest cost a second time.
Base valuation: At an assumed $1.33/£, consistent with the release’s currency reference, 187p per ordinary share becomes $4.97 per ADS. Applying 11.5x gives $57.20, rounded to a $57 target. At the $48.74 reaction close, the stock trades at 9.8x our FY2027 estimate. The target offers 16.9% price upside. Holding the annual dividend at 70p as an explicit twelve-month assumption gives approximately $1.86 per ADS, or 3.8% before fees and tax, taking expected total return to about 20.8%.
The multiple falls from July’s 12.0x to 11.5x as confidence in the loss-of-exclusivity bridge weakens. The unchanged cost programme and current Specialty growth justify retaining some of that premium; unresolved prevention data and the larger interest bill argue against keeping all of it. We expect the base-case return to exceed the S&P 500 over twelve months, without requiring sector-leading valuation or rapid Hibsago adoption.
Downside: At 175p FY2027 EPS, a 9.5x multiple and $1.25/£, value is approximately $42 per ADS. This assumes weaker launch conversion and pricing, together with a larger discount for HIV uncertainty. It implies about 14% price downside and roughly 10% negative total return after an unchanged dividend. The skew remains favourable, but repeated negative HIV developments or failure of launch conversion would erode it.
Thesis Scorecard Post-Earnings
| Standing pillar | Judgment | Status | Evidence and consequence |
|---|---|---|---|
| Bull 1: Specialty mix shift | Confirmed | ON TRACK | 15% growth; current franchise funds reinvestment |
| Bull 2: Long-acting HIV as LOE insurance | Challenged | ON TRACK → AT RISK | Prevention analysis ongoing; treatment pathway retained |
| Bull 3: Late-stage pipeline density | Confirmed | ON TRACK | Hibsago approval and 18 of 22 pivotal starts; uptake still matters |
| Bull 4: Valuation and capital return | Mixed | AT RISK | Attractive earnings multiple; debt and restructuring constrain buybacks |
| Bear 1: Dolutegravir loss of exclusivity | Risk rises | CONTAINED → EMERGING | Treatment data pending; prevention uncertainty reduces confidence in succession |
| Bear 2: Earnings quality | Confirmed | EMERGING | Inventory, royalties and spending phasing support the beat |
| Bear 3: Vaccines comp wall | Confirmed | CONTAINED → EMERGING | Shingrix declines despite US inventory support |
Overall: The thesis weakens relative to July, with conviction reduced from 7 to 6. Two explicit prior downside tests were avoided: General Medicines recovered and Hibsago’s label was broader than the feared restriction. The third, adverse 2027 margin guidance, has not been established because that guidance remains absent. The new HIV uncertainty deserves its own downgrade in confidence; it should not be mislabelled as a trigger that July had already defined.
Action: Maintain Outperform at a reduced $57 target. The next evidence that could change the view is the year-end regulatory discussion on EXTEND, the 2027 CUATRO readout, post-October Exdensur paid-sales acceleration and the full 2027 margin and financing guide. A loss of confidence in treatment as well as prevention, or launch growth insufficient to absorb pricing and financing costs, would undermine the return case. For now, the lower share price still compensates for the higher uncertainty.